MedTrace Logo

Von Willebrand Factor and Protein C Ratio in Graft Function After Liver Transplant

NCT04324255 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1199

Last updated 2020-03-27

No results posted yet for this study

Summary

In liver cirrhosis (LC),the activity of von Willebrand factor (vWF)-cleaving enzyme ADAMTS13 is reduced in LC patients and consequent progression of liver injury. Remarkably, it has been reported that a severe vWF/ADAMTS13 imbalance develops during liver transplantation (LT) and persists even after LT. Such changes are thought to contribute to postoperative thrombotic complications, which may lead to early adverse events of thrombotic microangiopathy after living-donor LT (LDLT). We investigated whether vWFPCR could predict EAD or graft failure following LT and compared it with FVIIIPCR, procoagulant, such as vWF and FVIII and anticoagulant, such as PC.

Conditions

  • Liver Transplant; Complications

Interventions

PROCEDURE

LT

Liver transplantation

Sponsors & Collaborators

  • Asan Medical Center

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-01
Primary Completion
2016-12-30
Completion
2020-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04324255 on ClinicalTrials.gov